Security
Jade Biosciences, Inc. Common Stock · JBIO
JBIONASDAQCommon stockCurrentCIK 1798749Updated Oct 29, 2026
Name history
Aerovate Therapeutics, Inc. · through Apr 30, 2025
JBIO price & chart
Loading TradingView…
NASDAQ:JBIO on TradingView ↗About the company
Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an anti-IFN-ß monoclonal antibody. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.
In the news
Jade Biosciences to Participate in Upcoming Conferences ↗
Seeking Alpha
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis - Slideshow ↗
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript ↗
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript ↗
Recent filings
SCHEDULE 13G filing
Other Events
Items 8.01
SCHEDULE 13G/A - filed by Venrock Healthcare Capital Partners III, L.P. regarding Jade Biosciences, Inc.
SCHEDULE 13G/A - filed by Bellevue Group AG regarding Jade Biosciences, Inc.
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding Jade Biosciences, Inc.
Entry into a Material Definitive Agreement
Items 1.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 202,450,000Source | 90,959,000Source | 472,113,000Source | 223,968,000Source | 111,694,000Source | 319,433,000Source | 77,533,000Source | 106,821,000Source | 349,781,000Source | 80,332,000Source | 127,418,000Source | 135,301,000Source |
| Property, Plant and Equipment, NetUSD | 176,000Source | 14,000Source | 144,000Source | 147,000Source | 232,000Source | 157,000Source | 2,000Source | 260,000Source | 170,000Source | 6,000Source | 288,000Source | 242,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 50,106,000Source | 31,115,000Source | 107,250,000Source | 220,942,000Source | 31,069,000Source | 55,085,000Source | 44,220,000Source | 9,122,000Source | 88,438,000Source | 33,751,000Source | 23,491,000Source | 22,397,000Source |
| Assets, CurrentUSD | 201,360,000Source | 90,605,000Source | 471,251,000Source | 222,984,000Source | 110,760,000Source | 318,517,000Source | 77,373,000Source | 103,239,000Source | 348,816,000Source | 80,117,000Source | 124,232,000Source | 131,496,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,455,000Source | 1,875,000Source | 10,046,000Source | 2,042,000Source | 6,558,000Source | 7,222,000Source | 1,163,000Source | 3,905,000Source | 12,658,000Source | 1,494,000Source | 1,793,000Source | 2,276,000Source |
| Operating Lease, Right-of-Use AssetUSD | 740,000Source | 259,000Source | 649,000Source | 777,000Source | 621,000Source | 690,000Source | 158,000Source | 725,000Source | 726,000Source | 209,000Source | 614,000Source | 1,003,000Source |
| Other Assets, NoncurrentUSD | 174,000Source | 81,000Source | 69,000Source | 60,000Source | 81,000Source | 69,000Source | — | 2,597,000Source | 69,000Source | — | 2,284,000Source | 2,560,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 23,104,000Source | 10,466,000Source | 32,198,000Source | 22,412,000Source | 17,296,000Source | 22,971,000Source | 2,487,000Source | 15,917,000Source | 17,263,000Source | 3,898,000Source | 17,962,000Source | 8,558,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,000Source | 3,000Source | 6,000Source | 3,000Source | 3,000Source | 5,000Source | 3,000Source | 3,000Source | 5,000Source | 3,000Source | 3,000Source | 2,000Source |
| Additional Paid in CapitalUSD | 321,769,000Source | 307,888,000Source | 711,089,000Source | 318,857,000Source | 305,863,000Source | 511,554,000Source | 310,563,000Source | 277,544,000Source | 506,771,000Source | 309,378,000Source | 272,640,000Source | 215,110,000Source |
| Retained Earnings (Accumulated Deficit)USD | -142,457,000Source | -227,622,000Source | -270,522,000Source | -117,282,000Source | -211,385,000Source | -214,757,000Source | -235,570,000Source | -186,610,000Source | -174,389,000Source | -233,052,000Source | -163,424,000Source | -87,903,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 29,000Source | 224,000Source | -660,000Source | -24,000Source | -83,000Source | -342,000Source | 50,000Source | -33,000Source | 129,000Source | 105,000Source | 237,000Source | -466,000Source |
| Stockholders' Equity Attributable to ParentUSD | 179,346,000Source | -16,863,000Source | 439,915,000Source | 201,556,000Source | -589,000Source | 296,462,000Source | -83,510,000Source | 90,904,000Source | 332,518,000Source | 76,434,000Source | 109,456,000Source | 126,743,000Source |
| Liabilities and EquityUSD | 202,450,000Source | 90,959,000Source | 472,113,000Source | 223,968,000Source | 111,694,000Source | 319,433,000Source | 77,533,000Source | 106,821,000Source | 349,781,000Source | 80,332,000Source | 127,418,000Source | 135,301,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 22,357,000Source | 10,315,000Source | 31,570,000Source | 21,620,000Source | 17,020,000Source | 22,292,000Source | 2,417,000Source | 15,518,000Source | 16,539,000Source | 3,828,000Source | 17,637,000Source | 7,782,000Source |
| Operating Lease, Liability, CurrentUSD | — | 459,000Source | — | — | 475,000Source | — | 312,000Source | 445,000Source | — | 417,000Source | 420,000Source | 385,000Source |
| Accounts Payable, CurrentUSD | 1,350,000Source | 908,000Source | 6,579,000Source | 7,586,000Source | 4,179,000Source | 3,979,000Source | 69,000Source | 3,313,000Source | 2,151,000Source | 224,000Source | 2,396,000Source | 2,575,000Source |
| Operating Lease, Liability, NoncurrentUSD | 747,000Source | 81,000Source | 628,000Source | 792,000Source | 206,000Source | 679,000Source | — | 329,000Source | 724,000Source | — | 255,000Source | 705,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 14,012,000Source | — | 14,922,000Source | 8,091,000Source | — | 14,852,000Source | — | — | 9,419,000Source | — | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 88,700,000Source | — | — | 104,200,000Source | — | 76,200,000Source | 99,300,000Source | — | 78,600,000Source | 122,400,000Source | 129,200,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 359,000Source | 43,000Source | 206,000Source | 302,000Source |
| Short-term InvestmentsUSD | 148,799,000Source | 57,615,000Source | 353,955,000Source | — | 73,133,000Source | 256,210,000Source | 31,990,000Source | 90,212,000Source | 247,720,000Source | 44,872,000Source | 98,948,000Source | 106,823,000Source |
| Preferred Stock, Value, Issued | —Source | — | — | —Source | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -25,175,000Source | -16,277,000Source | -55,765,000Source | -32,134,000Source | -40,368,000Source | -38,169,000Source | -127,410,000Source | -69,628,000Source | -75,521,000Source | -51,511,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 4,295,000Source | 27,000Source | 13,606,000Source | 3,895,000Source | 7,405,000Source | 2,423,000Source | 20,009,000Source | 11,311,000Source | 11,906,000Source | 5,476,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | 298,000Source | — | — | 2,328,000Source | 2,677,000Source | 361,000Source | -2,172,000Source | -164,000Source | 1,368,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -44,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | -6,802,000Source | — | — | -24,081,000Source | -18,757,000Source | -94,689,000Source | -71,196,000Source | -56,778,000Source | -39,122,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | 0Source | — | — | -8,470,000Source | 12,850,000Source | -247,006,000Source | 56,029,000Source | 11,876,000Source | 6,926,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 196,000Source | — | 142,000Source | 195,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | 94,772,000Source | — | — | -795,000Source | -700,000Source | 360,768,000Source | 25,427,000Source | 45,996,000Source | 396,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 189,111,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | 87,970,000Source | — | — | -33,353,000Source | -19,457,000Source | 19,052,000Source | 10,260,000Source | 1,094,000Source | -31,800,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 4,295,000Source | 2,003,000Source | 13,606,000Source | 3,895,000Source | 7,405,000Source | 2,423,000Source | 20,009,000Source | 11,311,000Source | 11,906,000Source | 5,476,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 88,700,000Source | — | — | — | 76,200,000Source | — | 78,600,000Source | 122,400,000Source | 129,200,000Source |
| DepreciationUSD | — | — | — | — | — | — | 9,000Source | 4,000Source | 26,000Source | 282,000Source | 96,000Source | 68,000Source |
| General and Administrative ExpenseUSD | — | — | 5,391,000Source | 1,384,000Source | 8,851,000Source | 5,231,000Source | 7,392,000Source | 3,361,000Source | 20,421,000Source | 21,409,000Source | 17,190,000Source | 14,615,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 15,000Source | 0Source | 16,000Source | — | 58,000Source | 55,000Source | 56,000Source | 25,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -25,175,000Source | -16,277,000Source | -55,765,000Source | -32,134,000Source | -40,368,000Source | -38,169,000Source | -127,410,000Source | -69,628,000Source | -75,521,000Source | -51,511,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -19,088,000Source | -16,277,000Source | — | — | — | -38,169,000Source | -100,136,000Source | -69,628,000Source | -75,521,000Source | -51,511,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,226,000Source | -1,312,000Source | 3,166,000Source | -4,356,000Source | 3,093,000Source | -14,785,000Source | -13,810,000Source | 5,023,000Source | — | — |
| Operating ExpensesUSD | — | — | 27,401,000Source | 14,965,000Source | 58,916,000Source | 27,778,000Source | 43,445,000Source | 23,384,000Source | 113,542,000Source | 74,596,000Source | 81,409,000Source | 53,237,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 26,000Source | 8,000Source | 83,000Source | — | 400,000Source | 400,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 256,000Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | -28,000Source | 0Source | -62,000Source | 0Source | -9,000Source | 0Source | -8,000Source | -19,000Source | 5,944,000Source | 1,751,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 73,898,000Source | — | 261,194,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 23,942,000Source | 44,888,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 45,000Source | — | 88,000Source | 1,484,000Source | 986,000Source | 617,000Source |
| Unrealized Gain (Loss) on Investments | — | — | —Source | —Source | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -27,401,000Source | -14,965,000Source | -58,916,000Source | -27,778,000Source | -43,445,000Source | -23,384,000Source | -113,542,000Source | -74,596,000Source | -81,409,000Source | -53,237,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -28,000Source | 0Source | -62,000Source | 0Source | -9,000Source | 0Source | -8,000Source | -19,000Source | 5,944,000Source | 1,751,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | -55,750,000Source | -32,134,000Source | -40,352,000Source | -38,169,000Source | -127,352,000Source | -69,573,000Source | -75,465,000Source | -51,486,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 15,000Source | 0Source | 16,000Source | — | 58,000Source | 55,000Source | 56,000Source | 25,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -25,175,000Source | -16,277,000Source | -55,765,000Source | -32,134,000Source | -40,368,000Source | -38,169,000Source | -127,410,000Source | -69,628,000Source | -75,521,000Source | -51,511,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.48Source | -5.16Source | -0.76Source | -0.86Source | -0.57Source | -12.1Source | -3.19Source | -2.44Source | -2.87Source | -2.1Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.48Source | -5.16Source | -0.76Source | -0.86Source | -0.57Source | -12.1Source | -3.19Source | -2.44Source | -2.87Source | -2.1Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 39,584,489Source | 3,155,500Source | 61,050,775Source | 28,431,158Source | 57,777,165Source | 3,155,500Source | 31,359,958Source | 28,582,194Source | 26,331,630Source | 24,472,104Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 39,584,489Source | 3,155,500Source | 61,050,775Source | 28,431,158Source | 57,777,165Source | 3,155,500Source | 31,359,958Source | 28,582,194Source | 26,331,630Source | 24,472,104Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 102,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 5,391,000Source | 1,384,000Source | 8,851,000Source | 5,231,000Source | 7,392,000Source | 3,361,000Source | 20,421,000Source | 21,409,000Source | 17,190,000Source | 14,615,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -127,588,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 2,254,000Source | 388,000Source | 3,228,000Source | 1,828,000Source | 3,102,000Source | 615,000Source | 7,782,000Source | 5,042,000Source | 5,945,000Source | 1,830,000Source |
| Labor and Related ExpenseUSD | — | — | — | — | — | — | — | — | — | 19,512,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -19,088,000Source | -16,277,000Source | — | — | — | -38,169,000Source | -100,136,000Source | -69,628,000Source | -75,521,000Source | -51,511,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,226,000Source | -1,312,000Source | 3,166,000Source | -4,356,000Source | 3,093,000Source | -14,785,000Source | -13,810,000Source | 5,023,000Source | — | — |
| Operating ExpensesUSD | — | — | 27,401,000Source | 14,965,000Source | 58,916,000Source | 27,778,000Source | 43,445,000Source | 23,384,000Source | 113,542,000Source | 74,596,000Source | 81,409,000Source | 53,237,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 26,000Source | 8,000Source | 83,000Source | — | 400,000Source | 400,000Source |
| Research and Development ExpenseUSD | — | — | 22,010,000Source | 13,581,000Source | 50,065,000Source | 22,547,000Source | 36,053,000Source | 20,023,000Source | 93,121,000Source | 53,187,000Source | 64,219,000Source | 38,622,000Source |
| Restructuring and Related Cost, Incurred CostUSD | — | — | — | — | — | — | — | — | — | 6,700,000Source | — | — |
Offerings
Registration 333-295662
Registration 333-295665
Registration 333-292369
Registration 333-291541
Registration 333-283562
Filing attachments
d40629dex991.htm · 8-K · 2026-08-10
EX-99.1 2 d40629dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027 Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin …
Read attachment ↗d127137dex991.htm · 8-K · 2026-06-26
EX-99.1 2 d127137dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors San Francisco and Vancouver, British Columbia, June 26, 2026 - Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Mark Eisner, M.D., M.P.H., to its Board of Directors, effective June 25,…
Read attachment ↗d103726dex991.htm · 8-K · 2026-06-04
EX-99.1 4 d103726dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Jade Biosciences Announces Proposed Underwritten Public Offering San Francisco and Vancouver, British Columbia - June 3, 2026 - Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of …
Read attachment ↗d103726dex992.htm · 8-K · 2026-06-04
EX-99.2 5 d103726dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Jade Biosciences Announces Pricing of Public Offering of Common Stock San Francisco and Vancouver, British Columbia - June 3, 2026 - Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the pricing of a public offering of 10,000,000 shares of its common stock. The shares of common stock are being …
Read attachment ↗d124589dex991.htm · 8-K · 2026-06-01
EX-99.1 2 d124589dex991.htm EX-99.1 EX-99.1 JADE101 Phase 1 Interim Data Conference Call June 1, 2026 Nasdaq: jbio Exhibit 99.1 Disclaimers Forward Looking Statements Certain statements contained in or made orally during this presentation, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. T…
Read attachment ↗d132368dex45.htm · S-3 · 2026-05-07
Exhibit 4.5 JADE BIOSCIENCES, INC. INDENTURE Dated as of ___________, 20___ [_______________] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section …
Read attachment ↗